Dosing and Administration

INDICATION

DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

Simple dosing with DESCOVY FOR PrEP1

One pill, once daily, with no food requirements

The DESCOVY pill is smaller than TRUVADA2

DESCOVY® (emtricitabine and tenofovir alafenamide) pill
  • DESCOVY®

(emtricitabine 200mg/tenofovir alafenamide 25mg) tablets.

Not actual size.
Actual size is 13mm x 6mm.

TRUVADA® (emtricitabine/tenofovir disoproxil fumarate) pill
  • TRUVADA®

(emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) tablets.

Not actual size.
Actual size is 19mm x 8.5mm.

Please click here for full Prescribing Information for TRUVADA, including BOXED WARNING.

DESCOVY FOR PrEP fits into your patients' daily routine.

DESCOVY FOR PrEP can be used in patients with estimated CrCl ≥30 mL/min.1


Screening & Monitoring Info